Diabetes Conferences | Diabetes Congress

Theme: Explore the Latest Trends and Advances in Diabetes Management

Diabetes Meeting 2023

Diabetes Meeting 2023

Dear Participants,

On October 02-03, 2023 London, UK, we will be delighted to welcome you to the 34th International Congress on Prevention of Diabetes and Complications. This year's Diabetes Meeting conference topic, "Explore the Latest Trends and Advances in Diabetes Management," emphasises the value of a coordinated and all-encompassing strategy for combating the global Diabetic epidemic.

Researchers, practitioners, decision-makers, and business executives will be able to discuss the most recent developments in the area of diabetes medicine at this conference. With keynote addresses, plenary sessions, and poster presentations on diabetes prevention, management, and therapy, we have created a thorough schedule. In addition to the scientific program, the conference will offer a lot of possibilities for networking and cooperation, giving attendees the chance to connect with peers from across the world and forge new partnerships and collaborations.

We want to thank everyone who helped make this conference possible, including the presenters, sponsors, and attendees. We are sure that the talks and insights shared at the conference will help create fresh, cutting-edge strategies for combating the obesity pandemic around the world. We are excited to have you in Amsterdam and look forward to a successful meeting.

Diabetes Conferences 2023 | Diabetes Events | Scientific Conferences on Diabetes | Best Diabetes Conferences | Diabetes 2023 Events

With the amalgamation of peerless speakers of Diabetes 2021 Conference Series is privileged to announce its “34^th International Congress on Prevention of Diabetes and Complications” which will be held on October 02-November 03, 2023 in London, UK. We cordially welcome all the eminent researchers, students and delegates to take part in this upcoming Diabetes conference to witness invaluable scientific discussions and contribute to future innovations in the field of Diabetes.

According to WHO, about 60 million people with diabetes in the European Region. About 10.3% of men and 9.6% of women aged 25 years and over. Worldwide, high blood glucose kills about 3.4 million people annually amongst 80% of these deaths occur in low- and middle-income countries, and almost half are people aged under 70 years. WHO projects diabetes deaths will double between 2005 and 2030. The overall risk of death among people with diabetes is at least double the risk of their peers without diabetes. Reflecting this imperative, Conference Series is all set to host Diabetes webinar this year which will provide the future leadership in this key area for global health.

Diabetes Meeting 2023 will focus on the latest and exciting innovations in all areas of Diabetes research which offers a unique opportunity for investigators across the globe to meet, network, and perceive new scientific innovations. The two days conference includes workshops, symposiums, special keynote sessions conducted by eminent and renowned speakers who excel in the field of Diabetes which include: Advanced Technologies for Treatment of Diabetes, Emerging Focus in Diabetes Research, Diabetes Research in Clinical Practice, Computational Biology of Diabetes, Cell Therapy for Diabetes and its Complications, Genetics of Diabetes, Diabetes Management, Transplantation for Diabetes, Endocrinology Disorders and Treatment.

Young Research’s Awards at Diabetes Meeting 2023 for the Nomination: Young Researcher Forum - Outstanding Masters/Ph.D./Post Doctorate thesis work Presentation, only 25 presentations acceptable at the Diabetes Meeting 2023 young research forum.

Benefits:

Young Scientist Award recognition certificate and memento to the winners
Our conferences provide best Platform for your research through oral presentations.
Learn about career improvement with all the latest technologies by networking.
Young Scientists will get appropriate and timely information by this Forum.
Platform for collaboration among young researchers for better development.
Provide an opportunity for research interaction and established senior investigators across the globe in the field
Share the ideas with both eminent researchers and mentors.

It’s a great privilege for young researchers to learn about the research areas for expanding their research knowledge.

Diabetes Meeting 2023 provides best platform to expand your network, where you can meet scientists, authorities and CROs from around the world. It’s your time to grab the opportunity to join Diabetes conferences for promoting your research article and to facilitate prestigious award in all categories. In this fame, we look forward for your contribution and astonishing dedication to make our conference more successful.

Track 01: Complications associated with Diabetes

The term diabetes mellitus describes several diseases of abnormal carbohydrate metabolism that are characterized by hyperglycaemia. It is associated with a relative or absolute impairment in insulin secretion, along with varying degrees of peripheral resistance to the action of insulin. They are derived after doing many clinical trials on animal models. Every few years, the diabetes community revaluates the current recommendations for the classification, diagnosis, and screening of diabetes, reflecting new information from research and clinical practice which in turns help in understanding current prevention and treatment options and cost effectiveness in treatment and prevention of Diabetes. People with type1 and type2 diabetes have an increased risk of developing a number of serious health problems. Consistently high blood glucose levels can lead to serious diseases affecting the Macro vascular and micro vascular complications. In addition, people with diabetes also have a higher risk of developing infections. In almost all high-income countries, diabetes is a leading cause of cardiovascular disease, blindness, kidney failure, and lower limb amputation. Maintaining blood glucose levels, blood pressure, and cholesterol at or close to normal can help delay or prevent diabetes complications. Hypoglycaemia and Hyperglycaemia are the other two factors are the two major complications of diabetes where hyperglycaemia is an acute complication sharing many symptoms and hypoglycaemia is an acute complication of several diabetes treatments. Glycosylated haemoglobin is a form of haemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.

Type 1 diabetes
Type 2 diabetes
Hypoglycaemia
Hyperglycaemia
Macro vascular complications
Micro vascular complications
Cardiovascular disease

Track 02: Genetics of Diabetes

Diabetes constitutes a major public health problem. Although substantial progress has been made in defining the genetics of metabolic syndrome risk for specific subtypes of diabetes (e.g., maturity-onset diabetes of the young), the majority of genetic risk of diabetes (for type 1 and type 2) remain unresolved. This review focuses on the current knowledge of the genetic basis of diabetes and its complications, specifically diabetic nephropathy (DN), recent advances in genetics of diabetes, diabetes in ethnic groups, genetic lifestyle interactions and understanding the genetics of Diabetes. Ultimately, identification of genes that contribute to risk (or protection) of diabetes and its complications will allow identification of patients who have diabetes and are at risk and targeted treatment/interventional strategies. Diabetic amyotrophic is a disabling illness that is distinct from other forms of diabetic neuropathy.

Type 1 diabetes
Type 2 diabetes
Diabetic nephropathy
Diabetic amyotrophic
Denetics of diabetes

Track 03: Advanced Technologies for the Treatment of Diabetes

The concept of 'new technologies' for type 1 diabetes and new discovery and advanced type 2 diabetes treatment has expanded in recent years at a rate that some might consider comparable to 'Moore’s Law', and the sheer number of new technologies entering into the type 1 diabetes marketplace is also growing at a remarkable rate. From the patient’s perspective, this is not only exciting but can lead to a sense of optimism. Technologies that today are growing commonplace (e.g. insulin pumps, rapid HbA1c monitoring, etc come under new therapeutic mechanisms of diabetes. Indeed, it could be argued that the major advances in type 1 diabetes care made within the last quarter of a century have come from technology rather than biology. At the same time, not all new technologies succeed (e.g. the Glucowatch), regardless of their purported promise. Both type 1 diabetes patients and their healthcare providers will soon see a series of further advanced medical technologies used in hospital and new technologies and novel therapies in diabetes treatment whose basis is tied to the notion of improving the lives of those with the disease.

Insulin pumps
Glucowatch
HbA1c monitoring
Advanced medical technologies

Track 04: Diabetes Management

The main goal of diabetes management is, as far as possible, to restore carbohydrate metabolism to a normal state. To achieve this goal, individuals with an absolute deficiency of insulin require insulin replacement therapy, which is given through injections or an insulin pump. Insulin resistance, in contrast, can be corrected by dietary modifications and exercise. Other goals of diabetes management are to prevent or treat the many complications that can result from the disease itself and from its treatment. Healthy eating is a cornerstone of healthy living — with or without diabetes. But if you have diabetes, you need to know Impact of Food and Nutrition, impact of physical activity and yoga therapy in Diabetes Management. Diabetic foot complications result in huge costs for both society and the individual patients. Few reports on the health-economic consequences of diabetic foot infections have been published. Standards of medical care in Diabetes increased when compared to previous year.

Carbohydrate metabolism
Insulin replacement therapy
Dietary modifications
Exercise
Nutrition
Yoga therapy

Track 05: Emerging Focus in Diabetes Research

Diabetes is a common chronic disease that imposes considerable demands on the individual healthcare system. People with diabetes have a higher rate of cardiovascular disease than those without diabetes and are at increased risk for kidney failure, lower limb amputation and blindness. Obesity is a significant risk factor for diabetes and the prevalence of obesity in children and adults has dramatically increased in the past four decades. Diabetic dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. The characteristic features of diabetic dyslipidemia are a high plasma triglyceride concentration, low HDL cholesterol concentration and increased concentration of small dense LDL-cholesterol particles. In order to investigate the bioinformatics tools and methodologies used to in diabetes research, at first, this was difficult to do because it did not have a preconceived idea about how the research would be organized and how bioinformatics tools would be described or identified in the research. To get started, we ran several cursory searches using basic search terms such as bioinformatics and diabetes (research) through several databases to see what types of articles were returned. Diabesity can be defined as a metabolic dysfunction that ranges from mild blood sugar imbalance to full-fledged type 2 diabetes. A bolus dose is insulin that is specifically taken at meal times to keep blood glucose levels under control following a meal.

Diabetic dyslipidemia
Cholesterol
Metabolic dysfunction
Blood sugar imbalance

Track 06: Transplantation of Diabetes

Getting a new heart, liver, kidney, lung, or other organ can save your life. Sometimes, it can also lead to type 2 diabetes. Many people can stop taking steroids after 6 months or so. This may solve the problem. If scientists can develop safe immunosuppressant’s that always work, then many people with type 1 diabetes may choose to have pancreas transplants. Until then, many doctors think islet transplants are a better option even after performing clinical trials on islet transplants. Islets are clusters of cells in the pancreas that make insulin. In people with type 1 diabetes, islet cells are destroyed. Only 1-2% of the pancreas is made up of islet cells. In pancreatic islet transplantation, cells are taken from a donor pancreas and transferred into another person. Once implanted, the new islets begin to make and release insulin. Researchers hope that islet transplantation will help people with type 1 diabetes live without daily injections of insulin. A transplant of the pancreas is usually reserved for those with serious complications. Pancreas transplants are most often done when a patient also receives a new kidney. The pancreas transplant adds little further risk in this situation and offers big benefits. However, transplant surgery is risky. Each person needs to carefully weigh the potential benefits and risks. Xenotransplantation for the treatment of type 1 diabetes is the transplantation of living cells, tissues or organs from one species to another. Such cells, tissues or organs are called xenografts or xenotransplants. A bolus dose is insulin that is specifically taken at meal times to keep blood glucose levels under control following a meal. Bolus insulin needs to act quickly and so short acting insulin or rapid acting insulin will be used where as Conventional insulin therapy is a therapeutic regimen for treatment of diabetes mellitus which contrasts with the newer intensive insulin therapy.

Type 1 diabetes
Type 2 diabetes
Islet transplants
Pancreas
Xenotransplantation
Xenografts
Xenotransplants

Track 07: Diabetes Research in Clinical Practice

Novel therapeutic targets available for diabetes includes Incretin based therapies, oral therapeutic agents like secretagogues, beta cell regeneration & proliferation and stem cell therapies. Embryonic stem cell and fetal precursor cell transplantation therapies are the major stem cell therapies available for Diabetes. Apart from the above, various computational approaches in Diabetes management control have been introduced recently which are playing an important role in identification of genes causing diabetes helping in Early Detection of Diabetes. These processes are also useful in studying the chemical etiologies of Diabetes uncovering various treatment prospects and model construction processes for survival prediction.

Incretin
Secretagogues
Beta cell regeneration
Stem cell therapies

Track 08: Computational Biology of Diabetes

Computational meta-analysis can link environmental chemicals to genes and proteins involved in human diseases, thereby elucidating possible aetiologies. The recent rapid development of a variety of analytical platforms based on mass spectrometry and nuclear magnetic resonance have enabled identification of complex metabolic Syndrome phenotypes. Continued development of bioinformatics and analytical strategies has facilitated the discovery of causal links in understanding the pathophysiology of diabetes and its complications.

Atiologies
Spectrometry
Syndrome phenotypes
Bioinformatics
Pathophysiology

Track 09: Risk Factors and Related Diseases of Diabetes

Diabetes is always accompanied by a number of serious health issues. Consistent increase in blood glucose levels can lead to serious diseases affecting the vital organs of body like heart and blood vessels, eyes, kidneys, nerves and teeth. In almost all high-income countries, diabetes is a leading cause of cardiovascular disease like diabetic cardiomyopathy being one of the major risk factor, blindness, kidney failure, and lower limb amputation. Diabetic Retinopathy causes progressive damage to the retina in the patients with diabetes adding as the most vulnerable risk for the patient. Maintaining blood glucose levels, blood pressure, diabetic gastro paresis which has been reported to have the main cause as Diabetes Mellitus and cholesterol at or close to normal can help delay or prevent diabetes complications.

Blood glucose levels
Cardiovascular disease
Diabetic cardiomyopathy
Kidney failure
Diabetic Retinopathy
Diabetes Mellitus
Cholesterol

Track 10: Endocrinology: Disorders and Treatment

Endocrinology is the study of hormones and the treatment of hormone based diseases. The endocrine glands produce chemicals called hormones. These hormones are released into the blood stream and exert their action by stimulating other organs in the body. However, Clinical trials on endocrinology look at new ways to prevent, detect, or treat disease. The major endocrine glands are the thyroid, pancreas, parathyroid, adrenal, gonad and pituitary. The hormones from these glands regulate growth, metabolism, blood pressure, reproduction as well as many other necessary functions. Early Diagnosis and Treatment of Endocrine Disorders, written by a distinguished panel of clinical experts and research scientists, focuses on the early signs and symptoms of common endocrine diseases, surveys the clinical testing needed for a diagnosis, and concisely presents the best current recommendations for therapy. Paediatric endocrinology is a medical subspecialty that studies and treats conditions affecting physical growth and sexual development in children, as well as diabetes and other disorders of the endocrine (hormone) glands.

Endocrine Disorders
Paediatric endocrinology
Early Diagnosis and Treatment
Endocrine (hormone) glands

Track 11: Diabetes Mellitus Type 1

Diabetes mellitus type 1 (otherwise called type 1 diabetes) is a type of diabetes mellitus that outcomes from the immune system annihilation of the insulin-delivering beta cells in the pancreas. The ensuing absence of hypoglycaemic agent prompts expanded aldohexose within the blood and pee. The established manifestations are regular pee, expanded thirst, expanded yearning, and weight reduction. The reason for diabetes type one is obscure. Type 1 diabetes is recognized from kind two from antibody testing. The C-peptide test, which measures endogenous insulin generation, can likewise be utilized. Organization of insulin is fundamental for survival. Insulin treatment must be proceeded with uncertainly and commonly does not disable ordinary every day exercises. Individuals are usually ready to freely take care of their diabetes; be that because it could, for a few these will challenge. Untreated, diabetes can bring about numerous confusions. Intense confusions incorporate diabetic ketoacidosis and non-ketotic hyperosmolar trance like state. Genuine end of the day complexities known with high glucose incorporate coronary unwellness, stroke, kidney disappointment, foot ulcers and harm to the eyes. Moreover, confusions could emerge from low aldohexose caused by extortionate hypoglycemic agent treatment. Diabetes mellitus type 1 represents around five-hitter and 100% of all diabetes cases.

Track 12: Diabetes Mellitus Type 2

Type 2 diabetes may be a long-term metabolic turmoil that's pictured by high aldohexose, insulin resistance, and relative absence of insulin. Basic aspect effects incorporate expanded thirst, incessant pee, and unexplained weight reduction. Indications could likewise incorporate swollen desire, feeling tired, and bruises that don't recuperate. Regularly indications go ahead gradually. Long haul complexities from high aldohexose incorporate coronary malady, strokes, diabetic retinopathy which can bring about visual impairment, kidney disappointment, and poor blood stream in the appendages which may prompt removals. The sudden onset of hyperosmolar hyperglycaemic state may happen; in any case, diabetic ketoacidosis is unprecedented. Type 2 diabetes is mostly preventable by staying a typical weight, practicing consistently, and eating legitimately. Treatment includes activity and dietary changes. In the event that aldohexose levels aren't sufficiently brought down, the medicine metformin is regularly suggested. Numerous individuals may in the end likewise require insulin infusions. In that on insulin, routinely check glucose levels is exhorted, in any case this may not be required in those taking pills. Bariatric surgery of times enhances diabetes within the people UN agency ar stout. Diabetes mellitus may be a devastating and sophisticated metabolic malady, expected to affect over 500 million people worldwide by the year 2030; up from 350 million in 2010. Approximately 95% of patients suffer from type 2 diabetes, and its prevalence is expected to increase in the future.

Track 13: Diabetes Research

Diabetes may be a common chronic illness that imposes right smart demands on the individual tending system. Individuals with polygenic disease have the next rate of disorder than those while not diabetes and are at multiplied risk for renal disorder, lower limb amputation and vision defect. Fleshiness may be an important risk issue for diabetes and also the prevalence of fleshiness in youngsters and adults has dramatically multiplied within the past four decades. Diabetic dyslipidemia is one among the foremost risk factors for disorder in diabetes. The characteristic options of diabetic dyslipidemia are a high plasma lipid concentration, low cholesterol concentration and multiplied concentration of tiny dense LDL-cholesterol particles. So as analysis to analyze the bioinformatics tools and methodologies accustomed in polygenic disease research, at first, this was tough to try and do as a result of it failed to have a preconceived notion concerning however the analysis would be organized and the way bioinformatics tools would be delineated or known within the analysis. To urge started, we tend to ran many perfunctory searches exploitation basic search terms like bioinformatics and diabetes (research) through many databases to examine what varieties of articles were came. Incapacity is outlined as a metabolic dysfunction that ranges from delicate glucose imbalance to full-fledged kind a type 2 diabetes. A bolus dose is internal secretion that's specifically taken at meal times to stay glucose levels in check following a meal.

Track 14: Diabetes Ophthalmology

Diabetic retinopathy is that the most typical diabetic disease and a number one explanation for visual impairment in adults within the U.S. It is caused by changes within the blood vessels of the membrane. The membrane is that the sensitive tissue at the rear of the attention. A healthy retina is necessary for good vision. Diabetic retinopathy is detected throughout an expanded eye communicating by associate degree specialist or specialist. A communicating by your primary doctor, during whom your eyes are not dilated, is not an adequate substitute for a full exam done by an ophthalmologist. Eye exams for individuals with polygenic disorder will include: sight testing. Diabetic retinopathy affects blood vessels within the sensitive tissue known as the membrane that lines the rear of the attention. It is the foremost common explanation for vision loss among individuals with polygenic disorder and therefore the leading explanation for vision impairment and visual impairment among working-age adults.

Diabetes can harm your eyes. It will harm the little blood vessels in your membrane, or the back of your eye. This condition is called diabetic retinopathy. Diabetes conjointly will increase your risk of eye disease and alternative eye issues. There is no cure for diabetic retinopathy. But optical device treatment surgical procedure is typically terribly effective at preventing vision loss if it's done before the membrane has been severely broken. Surgical removal of the vitreous gel (vitrectomy) may additionally facilitate improve vision if the membrane has not been severely broken. Diabetic Retinopathy Market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, supported by a CAGR of 14.4% during the forecast period 2014 to 2022.

“34^th International Congress on Prevention of Diabetes and Complications which is going to be held on October 02- October 03, 2023 in London, UK.

Diabetes Conferences 2023 invites all Academic Scientists, Leading Endocrinologists, Surgeons, Oncologists, Radiation Therapists, General Physicians, Dieticians, Primary Health care specialists, Internists, Pharmaceutical Industrial Delegates, talented young scientists, and student communities across the globe to attend European Diabetes conference under a single roof where networking and global partnering happens for the acceleration of future research.
Today’s Market Study of Diabetes in USA | Europe | Middle East | Asia Pacific
Europe: The number of people living with diabetes in Europe is expected to increase from 52 million in 2014 to 68.9 million by 2035, according to the International Diabetes Federation (IDF). Across Europe, around 1 in 11 adults is affected and this number is set to rise as the population ages.
USA: Diabetes Mellitus has been growing at an exponential rate and World Health Organization (WHO) estimates that the diabetic population is likely to reach 366 million in 2030. The United States is expected to have an increase of 102 per cent in the diabetic epidemic in 2030 when compared to 2000
Middle East: The rate of diabetes in parts of the Arabian Peninsula is over twice the global average rate, and much higher than some other areas of the Middle East and North Africa (MENA). And cases of type-2 diabetes outnumber cases of type-1 diabetes by a ratio of 10:1
Asia Pacific: The Asia-Pacific Diabetes Care Devices Market has been estimated at USD 2.461 Billion in 2015 and is projected to reach USD 3.518 billion by 2020, at a CAGR of 7.41% during the forecast period from 2015 to 2020
Diabetes is one of the fastest growing health challenges of the 21st century, with the number of adults living with diabetes having more than tripled over the past 20 years. In 2000, the global estimate of adults living with diabetes was 151 million. By 2009 it had grown by 88% to 285 million. Today, we calculate that 9.3% of adults aged 20–79 years – a staggering 463 million people – are living with diabetes. A further 1.1 million children and adolescents under the age of 20 live with type 1 diabetes. A decade ago, in 2010, the global projection for diabetes in 2025 was 438 million. With over five years still to go, that prediction has already been surpassed by 25 million will be 578 million adults with diabetes by 2030, and 700 million by 2045.
Type 1 diabetes is caused by an autoimmune reaction in which the body’s immune system attacks the insulin-producing beta cells of the pancreas. As a result, the body produces very little or no insulin.
Type 2 diabetes is the most common type of diabetes. Initially, hyperglycaemia (high blood glucose levels) is the result of the inability of the body’s cells to respond fully to insulin, a situation termed ‘insulin resistance’.
Gestational diabetes (GDM) is characterized by high blood glucose levels during pregnancy. It may occur at any time during pregnancy. Women who experience GDM face an increased risk of developing type 2 diabetes later in life. In addition, babies born to mothers with GDM also have a higher lifetime risk of obesity and developing type 2 diabetes themselves. This contributes to an intergenerational cycle of obesity and diabetes that seriously impacts the health of the entire population, and the generations to come.
Impaired glucose tolerance (IGT) is a condition of raised blood glucose levels above the normal range, but below the recommended diabetes diagnostic threshold. The terms ‘prediabetes’ and ‘non-diabetic hyperglycaemia’ are sometimes used as alternatives.
IGT is important because it:
Indicates a risk of developing type 2 diabetes in the future;
Denotes an already heightened risk of cardiovascular diseases;
Offers the opportunity for interventions that can lead to the prevention of type 2 diabetes. The estimated number of adults with IGT, and therefore at increased risk of developing type 2 diabetes, is 374 million. It is predicted to rise to 454 million by 2030 and to 548 million by 2045.
Insulin: Launch of generic versions of insulin and extensively growing demand for novel insulin in controlling the blood sugar levels in both type 1 and type 2 diabetes ate factors anticipated to fuel the growth of insulin segment in the market during the forecast period. In march 2019 Eli Lilly (key player) and company launched Lispro, a generic version of rapid-acting Humalog insulin which shall be available in the US by making it more accessible for diabetic patients. Additionally, growing investments in research and development by many government organizations and new product launches by many key players are like to boost the diabetes drugs market growth during the forecast period. For example, in 2019 Glenmark launched an oral anti-diabetic drug Remogliflozin in India which is considered as an effective drug treating adults with type-2 diabetes mellitus.
Growing urbanization and changing lifestyle habits (e.g. higher calorie intake, increasing consumption of processed foods, sedentary lifestyles) are contributory factors for the increasing prevalence of type 2 diabetes at a societal level. While global prevalence of diabetes in urban areas is 10.8%, in rural areas it is lower, at 7.2%. However, this gap is closing, with rural prevalence on the rise.
Diabetes increases the risk of early death: Approximately 4.2 million adults will die as a result of diabetes and its complications in 2019. This is equivalent to one death every eight seconds. Globally, 11.3% of deaths are due to diabetes. Almost half of these deaths are in people under 60 years of age. Half of the 463 million adults living with diabetes today are unaware that they have the condition, and are therefore at high risk of developing serious diabetes related complications.
Economic and social impact: Annual global health expenditure on diabetes is estimated to be at USD 760 billion under direct costs. It is projected that these direct costs will reach USD 825 billion by 2030 and USD 845 billion by 2045. The costs of treating complications account for over 50% of the direct health costs of diabetes. For example, management of diabetic ketoacidosis (DKA) is a considerable part of the cost to a country’s health system: treatment of a single DKA episode in the United Kingdom costs an estimated GBP 1,387 (around USD 1,750).

Age profile of diabetes

Working age (20-64) 72.0% three in four people living with diabetes (352 million people) are of working age (between 20 and 64 years old). This number is expected to increase to 417 million by 2030 and to 486 million by 2045.

Older people (65+) 27.8% in 2019, the estimated number of people over 65 years of age with diabetes is 111 million. One in five adults in this age group is estimated to have diabetes. It is projected that by 2030 the number of people over 65 with diabetes will further increase to 195 million. By 2045, it will reach 276 million.

Children and adolescents (0–19) 0.2% an estimated 1.1 million children and adolescents (aged under 20) have type 1 diabetes. There is some evidence that type 2 diabetes among children and adolescents is increasing in some countries.

Geographical profile

Age adjusted comparisons - Prevalence of diabetes in adults (20-79 years)

World

2045	9.6%
2030	9.2%
2019	8.3%

Europe

2045	7.8%
2030	7.3%
2019	6.3%

South & Central America

2045	9.9%
2030	9.5%
2019	8.5%

Middle East & North Africa

2045	13.9%
2030	13.3%
2019	12.2%

North America & Caribbean

2045	13.0%
2030	12.3%
2019	11.1%

Africa

2045	5.2%
2030	5.1%
2019	4.7%

South-East Asia

2045	12.6%
2030	12.2%
2019	11.3%

Western Pacific

2045	12.8%
2030	12.4%
2019	11.4%

Countries with the highest numbers of people with diabetes (2021) In 2021, the countries with the largest numbers of adults with diabetes are China, India and the United States of America, and are anticipated to remain so until 2030. It is projected that the number of people with diabetes in Pakistan will exceed that in the United States of America by 2045, moving the country to third place.

Rank	Country	No. of people with diabetes (millions)
1	China	116.4
2	India	77.0
3	USA	77.0
4	Pakistan	19.4
5	Brazil	16.8
6	Mexico	12.8
7	Indonesia	10.7
8	Germany	9.5
9	Egypt	8.9
10	Bangladesh	8.4

Low- and middle-income countries: The highest prevalence of diabetes in adults occurs in high-income countries, with an estimated 10.4% of the population having diabetes. The diabetes prevalence is 4% in low-income countries, and 9.5% in middle-income countries.

Improved education at the population-level, strong health systems, and effective policy frameworks are key to adequately address the primary risk factors of type 2 diabetes (such as poor eating habits, obesity and inadequate physical activity) and the high numbers of people living with undiagnosed diabetes

Societies Associated with Diabetes Research:

Spanish Diabetes Society (Spain)

FAND - Italian Association of Diabetics

Italian Association for the Defence of the Interests of Diabetics

Association of Diabetes

Association National Italian Diabetic Athletes

Italian Society of Diabetology

International Diabetes Federation- Italy

Primary Care Diabetes Society

Australian Diabetes Society

Emirates Diabetes Society

Society for Biomedical Diabetes Research

Immunology of Diabetes Society

American Association of Diabetes Educators

American Diabetes Association

The Asian Association for the Study of Diabetes

International Association of the Diabetes and Pregnancy Study Groups

Diabetes Association of Nigeria

Association of Children's Diabetes Clinicians

Canadian Diabetes Association

Diabetes Australia

Austrian Diabetes Association

Flemish Diabetes Association (Belgium

Association of Juvenile Diabetes (Brazil)

Canadian Diabetes Association

Juvenile Diabetes Foundation of Chile

Diabetological Colombian Federation

Croatian Diabetes Association

Union of Diabetics of Czech Republic

Estonian Diabetes Association

Finnish Diabetes Association

French Diabetics Association

German Diabetes Union

Hellenic Diabetes Association (Greece)

Hong Kong Diabetes Federation

Icelandic Diabetic Association

Diabetic Association of India

Diabetes Federation of Ireland

The Diabetes Association (Italy)

Japan Diabetes Society

Korean Diabetes Association

Lithuanian Diabetes Association

Luxembourg Diabetes Association

Maltese Diabetes Association (Malta)

Mexican Diabetes Federation

Netherlands Diabetes Association

Diabetes New Zealand

Norwegian Diabetes Association

Diabetes Philippines

Polish Diabetes Association

Diabetic Association of Portugal

Diabetic Society of Singapore

Diabetes South Africa

Swedish Diabetes Association

Swiss Diabetes Society

Diabetes UK

Diabetes Research Universities:

Diabetes Associations:

Diabetes Societies:

Attending the 34^th International Conference on Prevention of Diabetes is a fantastic opportunity for anybody interested in the field of prevention of diabetes and complications to acquire new knowledge, get new skills, and network with other experts from across the world.

Here are some reasons why you should attend:

Learn about the latest research and advancements in diabetes medicine: The conference will feature presentations and discussions by experts in the field, providing attendees with the latest information on research and advancements.
Gain new skills and knowledge: Attendees will have the opportunity to attend workshops and sessions on a range of topics related to diabetes medicine, providing them with new skills and knowledge that they can apply in their work.
Connect with other professionals: The conference will bring together researchers, clinicians, policymakers, and industry leaders from around the world, providing attendees with the opportunity to connect with others who share their interests and expertise.
Network with potential collaborators: The conference provides a platform for attendees to meet potential collaborators and build relationships that can lead to future collaborations and partnerships.
Share your own work: Attendees can submit their own research or case studies for presentation at the conference, providing an opportunity to share their work with others in the field and receive valuable feedback.
Explore Amsterdam: The conference will be held in Amsterdam, Netherlands, providing attendees with the opportunity to explore this beautiful city and its culture, history, and cuisine.

Attending the 34^th International Conference on Diabetes can be a valuable experience for anyone interested in the field of prevention of diabetes and complications, whether you are a researcher, clinician, policymaker, or industry professional.

Benefits of Participation

Advantages of Participating at our Conference

The Speaker and Abstract pages that Google creates on your profile under your name would give you global visibility.
Our Library of Abstracts receives more than 30,000 visits per month and 50 thousand views, which brings scholars and speakers to our Conference.
Meet and exchange ideas with thousands of thought leaders in obesity and nutritional health.
Each conference attendee would have a different motivation for engaging in one-on-one discussions with distinguished speakers and recognized keynote speakers.
At our Keynote presentations, you'll have the exceptional chance to hear what the world's foremost authorities on obesity are discovering.

Benefits of Participation for Speaker

Admiration for researchers' profile on a global scale.
Obtain points for your professional development.
Discover the most recent cutting-edge analysis.
Become lifelong friends through social and networking activities.
An opportunity to promote one page through the distribution of abstract books and flyers, which eventually receives 1 million views and greatly enhances your research profile.
Learn about new topics and studies that are unrelated to your primary subject of obesity and nutritional health by making a transition outside of your field of interest.
We've combined exceptional networking, education, and fun into one bundle.

Benefits of Participation for Delegate

Increased knowledge and understanding for professional development.
Attending webinars helps participants feel refreshed and energized.
Your participation in our conference will support the development of a new approach and philosophy that can be used to improve business or industry results.
Opportunities for OBESITY SUMMIT scholars and practitioners to connect and share new perspectives online and at conferences.

Benefit of Participation for Sponsor

The likelihood of new businesses would rise with exposure to the global marketplace.
A chance to showcase your business's most cutting-edge innovations, fresh products, or services to a large international audience.
Lead generation will help our webinar participants do more business.
To draw energy from others who have a similar purpose and objective, it's always helpful to have a network of co-workers and associates. Building a successful firm takes a lot of time, effort, and drive.
Webinars on obesity offer chances for greater thought and reflection, which might help you advance your business.
comparing the major organization's plans and advancing them.
Get answers to your company's queries and difficulties at our conference from reliable people.

Benefit of Association for Collaborators

No other website has this many visits, making Obesity the finest platform for bringing attention to society.
establishing enduring peer ties.
Your organization's logo, branding and marketing materials, promotional content, and the webinar banner will all work together to add 40% more subscribers and members to your list.
Your association will be greatly impacted by the visibility of our event to your company's placement in the Global Business forum.
Your representatives can interact with important delegates to update their knowledge and comprehension of your organization and services.
Information will be incorporated into obesity advertising materials such posters, brochures, pamphlets, and services that will be distributed to hospitals, universities, the general public, and researcher.

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	October 02-03, 2023
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1
Poster Opportunity Closed	Click Here to View